Giant cell tumours of the small bones of the hands and feet
- 1 June 2013
- journal article
- review article
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 95-B (6) , 838-845
Abstract
Giant cell tumours (GCTs) of the small bones of the hands and feet are rare. Small case series have been published but there is no consensus about ideal treatment. We performed a systematic review, initially screening 775 titles, and included 12 papers comprising 91 patients with GCT of the small bones of the hands and feet. The rate of recurrence across these publications was found to be 72% (18 of 25) in those treated with isolated curettage, 13% (2 of 15) in those treated with curettage plus adjuvants, 15% (6 of 41) in those treated by resection and 10% (1 of 10) in those treated by amputation.We then retrospectively analysed 30 patients treated for GCT of the small bones of the hands and feet between 1987 and 2010 in five specialised centres. The primary treatment was curettage in six, curettage with adjuvants (phenol or liquid nitrogen with or without polymethylmethacrylate (PMMA)) in 18 and resection in six. We evaluated the rate of complications and recurrence as well as the factors that influenced their functional outcome.At a mean follow-up of 7.9 years (2 to 26) the rate of recurrence was 50% (n = 3) in those patients treated with isolated curettage, 22% (n = 4) in those treated with curettage plus adjuvants and 17% (n = 1) in those treated with resection (p = 0.404). The only complication was pain in one patient, which resolved after surgical removal of remnants of PMMA. We could not identify any individual factors associated with a higher rate of complications or recurrence. The mean post-operative Musculoskeletal Tumor Society scores were slightly higher after intra-lesional treatment including isolated curettage and curettage plus adjuvants (29 (20 to 30)) compared with resection (25 (15 to 30)) (p = 0.091). Repeated curettage with adjuvants eventually resulted in the cure for all patients and is therefore a reasonable treatment for both primary and recurrent GCT of the small bones of the hands and feet.Cite this article: Bone Joint J 2013;95-B:838–45.Keywords
This publication has 31 references indexed in Scilit:
- Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bonesActa Orthopaedica, 2012
- Giant Cell Tumors of the Axial SkeletonSarcoma, 2012
- Giant cell tumor of the metacarpal bonesIndian Journal of Orthopaedics, 2011
- An Uncommon Presentation of Giant Cell TumorOman Medical Journal, 2011
- The efficacy of chemical adjuvants on giant-cell tumour of boneThe Journal of Bone and Joint Surgery. British volume, 2010
- Giant Cell Tumor of Bone: Risk Factors for RecurrenceClinical Orthopaedics and Related Research, 2010
- High-Speed Burring with and without the Use of Surgical Adjuvants in the Intralesional Management of Giant Cell Tumor of Bone: A Systematic Review and Meta-AnalysisSarcoma, 2010
- Giant cell tumour of bone: morphological, biological and histogenetical aspectsInternational Orthopaedics, 2006
- Phenol as an adjuvant for local control in the treatment ofgiant cell tumour of the boneEuropean Journal of Surgical Oncology, 1999
- Giant cell tumors of the bones of the handThe Journal of Hand Surgery, 1997